Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385687145> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4385687145 endingPage "85.19" @default.
- W4385687145 startingPage "85.19" @default.
- W4385687145 abstract "Abstract Type 1 diabetes is an untreatable autoimmune disease caused by the destruction of pancreatic beta cells by autoreactive T cells. The inhibition of inflammatory cytokines signaling via JAK inhibitors like Tofacitinib (Tofa) has shown promise in the prevention of this disease. To improve on drug bioavailability and reduce deleterious systemic exposure, we identified a lipid nanoparticle (LNp) formulation with favorable Tofa encapsulation efficiency and negligible cellular toxicity. Live animal imaging indicated these particles have the unique property of accumulating in lymphoid tissues, particularly in pancreatic and mesenteric lymph nodes when administrated via oral gavage. Spectral flow analysis revealed that multiple immune cells, like dendritic cells, T cells, and B cells, uptake the particles in these tissues. Short-term administration (5 gavages once every other day) of Tofa-LNp early (3-week-old) or late (10-week-old) in disease prone NOD mice promoted a significant delay of disease onset. Importantly, the therapeutic effect was associated with a profound increase in anergic CD4 T cells in the draining sites of LNp. Anergic cells have been known to form following stimulation in absence of co-stimulation, however, additional in vitro stimulation assays suggest a distinctive path of anergy induction promoted by blocking cytokine signaling. Overall, our results suggest an unexpected and novel immunomodulatory effect of JAK inhibition that warrants further investigation for the development of an effective treatment of type 1 diabetes." @default.
- W4385687145 created "2023-08-10" @default.
- W4385687145 creator A5001800952 @default.
- W4385687145 creator A5002858698 @default.
- W4385687145 creator A5008397618 @default.
- W4385687145 creator A5015132619 @default.
- W4385687145 creator A5016218098 @default.
- W4385687145 creator A5060850895 @default.
- W4385687145 creator A5074305766 @default.
- W4385687145 creator A5092793807 @default.
- W4385687145 date "2023-05-01" @default.
- W4385687145 modified "2023-09-27" @default.
- W4385687145 title "Prevention of Type 1 Diabetes via a Lipid Nanoparticle-Based JAK inhibitor Treatment that Involves Anergy Formation" @default.
- W4385687145 doi "https://doi.org/10.4049/jimmunol.210.supp.85.19" @default.
- W4385687145 hasPublicationYear "2023" @default.
- W4385687145 type Work @default.
- W4385687145 citedByCount "0" @default.
- W4385687145 crossrefType "journal-article" @default.
- W4385687145 hasAuthorship W4385687145A5001800952 @default.
- W4385687145 hasAuthorship W4385687145A5002858698 @default.
- W4385687145 hasAuthorship W4385687145A5008397618 @default.
- W4385687145 hasAuthorship W4385687145A5015132619 @default.
- W4385687145 hasAuthorship W4385687145A5016218098 @default.
- W4385687145 hasAuthorship W4385687145A5060850895 @default.
- W4385687145 hasAuthorship W4385687145A5074305766 @default.
- W4385687145 hasAuthorship W4385687145A5092793807 @default.
- W4385687145 hasBestOaLocation W43856871451 @default.
- W4385687145 hasConcept C126322002 @default.
- W4385687145 hasConcept C19317047 @default.
- W4385687145 hasConcept C203014093 @default.
- W4385687145 hasConcept C24998067 @default.
- W4385687145 hasConcept C2776090121 @default.
- W4385687145 hasConcept C2777575956 @default.
- W4385687145 hasConcept C2778013207 @default.
- W4385687145 hasConcept C2778886723 @default.
- W4385687145 hasConcept C2779062720 @default.
- W4385687145 hasConcept C2780130043 @default.
- W4385687145 hasConcept C502942594 @default.
- W4385687145 hasConcept C71924100 @default.
- W4385687145 hasConcept C8891405 @default.
- W4385687145 hasConcept C98274493 @default.
- W4385687145 hasConceptScore W4385687145C126322002 @default.
- W4385687145 hasConceptScore W4385687145C19317047 @default.
- W4385687145 hasConceptScore W4385687145C203014093 @default.
- W4385687145 hasConceptScore W4385687145C24998067 @default.
- W4385687145 hasConceptScore W4385687145C2776090121 @default.
- W4385687145 hasConceptScore W4385687145C2777575956 @default.
- W4385687145 hasConceptScore W4385687145C2778013207 @default.
- W4385687145 hasConceptScore W4385687145C2778886723 @default.
- W4385687145 hasConceptScore W4385687145C2779062720 @default.
- W4385687145 hasConceptScore W4385687145C2780130043 @default.
- W4385687145 hasConceptScore W4385687145C502942594 @default.
- W4385687145 hasConceptScore W4385687145C71924100 @default.
- W4385687145 hasConceptScore W4385687145C8891405 @default.
- W4385687145 hasConceptScore W4385687145C98274493 @default.
- W4385687145 hasIssue "1_Supplement" @default.
- W4385687145 hasLocation W43856871451 @default.
- W4385687145 hasOpenAccess W4385687145 @default.
- W4385687145 hasPrimaryLocation W43856871451 @default.
- W4385687145 hasRelatedWork W1591617358 @default.
- W4385687145 hasRelatedWork W1693189834 @default.
- W4385687145 hasRelatedWork W2413321539 @default.
- W4385687145 hasRelatedWork W3031852375 @default.
- W4385687145 hasRelatedWork W3037430002 @default.
- W4385687145 hasRelatedWork W3112940496 @default.
- W4385687145 hasRelatedWork W3157290455 @default.
- W4385687145 hasRelatedWork W3160168808 @default.
- W4385687145 hasRelatedWork W3216445796 @default.
- W4385687145 hasRelatedWork W4385687145 @default.
- W4385687145 hasVolume "210" @default.
- W4385687145 isParatext "false" @default.
- W4385687145 isRetracted "false" @default.
- W4385687145 workType "article" @default.